U.S. markets closed
  • S&P 500

    -64.76 (-1.72%)
  • Dow 30

    -486.27 (-1.62%)
  • Nasdaq

    -198.88 (-1.80%)
  • Russell 2000

    -42.72 (-2.48%)
  • Crude Oil

    -4.06 (-4.86%)
  • Gold

    -29.40 (-1.75%)
  • Silver

    -0.78 (-3.99%)

    -0.0145 (-1.47%)
  • 10-Yr Bond

    -0.0110 (-0.30%)

    -0.0398 (-3.54%)

    +0.9950 (+0.70%)

    +93.87 (+0.49%)
  • CMC Crypto 200

    -9.92 (-2.23%)
  • FTSE 100

    -140.92 (-1.97%)
  • Nikkei 225

    -159.30 (-0.58%)

Cannabis Industry Consuming Energy at An Alarming Rate: Investing in Solutions

HENDERSON, NV / ACCESSWIRE / April 9, 2019 / As per the report, "The Cannabis Energy Report: Current and Evolving State of Cannabis Energy Consumption" published by New Frontier Data, cannabis cultivation (legal and illicit) in the US consumed an estimated 4.1 million MWh of electricity in 2017. This is over 1% of total US electrical consumption! It's like 554,054 Israeli people consuming electricity for an entire year! Not only does this magnitude of energy use create an alarming impact on the environment, but it is a financial concern for the grower as electric costs are one of the top overhead expenses in a grow operation.

According to a 2014 report produced by the NPCC, indoor cannabis production can consume 4,000 to 6,000 kilowatt hours (kWh) of energy per kilogram of product. The equivalent would be a half year of average household consumption. The three main methods of cannabis cultivation used today are: outdoor, greenhouse, and indoor.

One company that could lead the way in solving this major issue is CleanSpark, Inc. (CLSK). The company has developed a microgrid power solution for the cannabis industry, which can reduce energy costs by up to 82%. This represents a huge potential revenue stream for the company. Due to this fact, the company has stated that marketing to cannabis companies is one of their top initiatives for 2019. Recently, the company closed on $5 million round of funding, engaged a firm to navigate their up listing and as far as currently operation go, announced the near completion of a $900k contract to install a CLSK microgrid at a U.S. Marine Corps Base and have been progressing on a $18.3 million deal with NYSE company MAC. This could be big, so start your research today.

Today we are highlighting: CleanSpark, Inc. (CLSK), Constellation Brands (STZ), Canopy Growth Corporation (CGC), Correvio Pharma Corp. (CORV), DURECT Corporation (DRRX).

In recent news, CleanSpark, Inc. (CLSK) (Market Cap: $142.312M; Share Price: $3.43) announced that it has delivered approximately $357,000 in custom electrical equipment to customers and received new orders of approximately $438,000 since the closing of the definitive agreement on January 22, 2019 to acquire the intellectual property of Pioneer Critical Power Inc. The custom equipment backlog has increased to approximately $3.9 million, an increase of approximately 8.3% from the backlog levels on the date of acquisition. Their acquisition of intellectual property of Pioneer Critical Power Inc. has already been a boon for their bottom line.


Beer and wine sales at Constellation Brands (STZ) (Market Cap: $36.509B; Share Price: $192.34) led their industry in the fiscal year ending February. However, the cash it made from booze was dwarfed by gains on its investment in the cannabis business Canopy Growth (CGC) (Market Cap: $14.659B; Share Price: $42.71) according to the company reported earnings of last week. Recently, it has signed an agreement with E. & J. Gallo Winery to divest approximately 30 brands from its wine and spirits portfolio principally priced at $11 retail and below and related facilities located in California, New York and Washington for $1.7 billion, subject to closing adjustments. The transaction is also subject to the satisfaction of certain closing conditions, including the receipt of regulatory approval, and is expected to close at the end of the company's first quarter of fiscal 2020. The company is trying to reposition itself in the competitive landscape.

Constellation Brands, Inc., together with its subsidiaries, produces, imports, and markets beer, wine, and spirits in the United States, Canada, Mexico, New Zealand, and Italy. The company sells wine across various categories, including table wine, sparkling wine, and dessert wine. It provides beer primarily under the Corona Extra, Corona Light, Modelo Especial, Modelo Negra, Modelo Chelada, Pacifico, and Victoria brands, as well as Funky Buddha, Obregon Brewery, and Ballast Point brands. Constellation is the No. 3 beer company in the U.S. with high-end, iconic imported brands such as the Corona and Modelo brand families and Pacifico.

Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, Bedrocan Canada, CraftGrow, and Foria brand names.


Correvio Pharma Corp. (CORV) (Market Cap: $119.742M; Share Price: $3.04), a specialty pharmaceutical company focused on commercializing hospital drugs, announced last week that seven abstracts featuring Zevtera/Mabelio (ceftobiprole medocaril sodium), an intravenous (IV) cephalosporin antibiotic with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria, were selected for presentation at the 29th European Congress of Clinical Microbiology and Infectious Disease (ECCMID), being held April 13-16, 2019 in Amsterdam , the Netherlands.

Correvio Pharma Corp., a specialty pharmaceutical company, provides various products to meet the needs of acute care physicians and patients worldwide. It develops, acquires, and commercializes various brands for the in-hospital acute care market segment. With a commercial presence and distribution network covering over 60 countries worldwide, Correvio develops, acquires and commercializes brands for the in-hospital, acute care market segment.


DURECT Corporation (DRRX) (Market Cap: $107.3M; Share Price: $0.6621) announced in March that it has commenced patient enrollment in a Phase 1b trial with oral DUR-928 in patients with NASH. DUR-928, the lead investigational product in the company's Epigenetic Regulator Program, is an endogenous, first-in-class small molecule, which may have broad applicability in chronic hepatic diseases such as NASH, acute organ injuries such as alcoholic hepatitis and acute kidney injury, and in inflammatory skin disorders such as psoriasis and atopic dermatitis.

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand.


Signed by

Priyanka Goel, CFA

Legal Disclaimer:

This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal Consulting has agreed to a three-month term consulting agreement with CLSK dated 9/12/18. The agreement calls for $10,000 in cash, and 30,000 restricted 144 shares of CLSK per month. Regal and CLSK have signed an amendment to extend the contract for twelve months starting 10/10/18, and increased the cash component to $20,000 per month. CLSK has paid an additional $12,000 for services provided in November. CLSK has paid an additional $88,000 for services provided in December. CLSK has paid an additional $100,000 for services for January. CLSK has paid an additional $100,000 for services for February. Regal was paid an additional $100,000 for March services. CLSK has paid All payments were made directly by Clean Spark, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. CLSK was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.

http://www.regalconsultingllc.com/full legal disclaimer/

Full Legal Disclaimer Click Here.

Contact Information:
Company Name: ACR Communication LLC.
Contact Person: Media Manager
Email: info@microcapspeculators.com
Phone: 1-702-720-6310
Country: United States

SOURCE: ACR Communication LLC

View source version on accesswire.com: